David Saunders, founding managing director of K2 Advisors, Franklin Templeton, explains how an allocation to hedged strategies can help investors outperform.
Recognise boutiques and passive investing
'Fear and greed' are two powerful drivers of stock markets, if the old Wall Street adage is to be believed. But how relevant is this saying in today's sophisticated financial world?
Focus on high quality companies
Active categories include healthcare and EM debt
Investors have stayed away from ethical funds as they supposedly have to give up returns in order to be ‘socially conscious'. Hardeep Tawakley reports
ESG factors can have positive impact on performance
After several years of bad news for the holders of open-ended but suspended life settlements funds, there is perhaps a glimmer of hope.
Encouraging bond issuance in the sector
Follows recent hire
Industry poses inherent risks
Worst losses since 2008
Addition to Megatrends range
The endeavour of projecting today's conditions, trends and relationships into the future inevitably results in errors of judgement – and economists continue to get caught out by the ever-changing market environment (often at the worst possible times).
Index plunged by more than 20% from peak
Q2 saw new lending of £507m
Toby Thompson, manager of the Brooks Macdonald Global Equity Income fund, analyses if equity investors are right to be concerned about the concentration of income from only a limited number of mega-cap companies
Former F&C Thames River managers Kristof Bulkai, Patrick Cadell and Hugo Rogers are to join Liontrust Asset Management to run global portfolios.
AXA IM has hired a sell-side healthcare specialist as the permanent replacement for former Health fund manager Gemma Game, who left the group last year.
Lessons from Silicon Valley's tech companies
Shell's planned £47bn takeover of BG Group could present ethical funds with a new dilemma as it removes one of their largest potential investments.
Aberdeen Asset Management is set to buy the remaining stake in its joint venture with SVG Capital, Aberdeen SVG Private Equity.
Woodford Investment Management, Ruffer, Sarasin and Invesco are among the groups backing a new share placing by Oakley Capital’s private equity trust.
Investors are showing increasing willingness to pay for R&D pipelines in biotech, explains AXA Framlington's Linden Thomson.